Wedbush Research Analysts Raise Earnings Estimates for TCRX

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at Wedbush raised their FY2028 earnings estimates for shares of TScan Therapeutics in a research report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.46 for the year, up from their previous estimate of $0.40. Wedbush has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 63.11% and a negative net margin of 1,188.88%. The company had revenue of $0.54 million during the quarter, compared to the consensus estimate of $1.55 million.

Several other research firms also recently commented on TCRX. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Tuesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Stock Performance

Shares of NASDAQ:TCRX traded down $0.18 on Thursday, hitting $5.07. The company had a trading volume of 10,004 shares, compared to its average volume of 246,218. The stock has a market cap of $268.56 million, a price-to-earnings ratio of -4.95 and a beta of 0.79. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. The stock has a 50 day moving average price of $5.34 and a 200 day moving average price of $6.52. TScan Therapeutics has a 1-year low of $3.73 and a 1-year high of $9.69.

Institutional Trading of TScan Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP purchased a new stake in TScan Therapeutics in the 2nd quarter valued at about $70,000. SG Americas Securities LLC purchased a new stake in shares of TScan Therapeutics during the third quarter valued at approximately $78,000. The Manufacturers Life Insurance Company purchased a new position in TScan Therapeutics in the second quarter worth $90,000. MetLife Investment Management LLC grew its stake in TScan Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after purchasing an additional 13,164 shares during the period. Finally, Cornercap Investment Counsel Inc. bought a new position in TScan Therapeutics in the 2nd quarter valued at $134,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

Insider Buying and Selling at TScan Therapeutics

In related news, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was bought at an average cost of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the transaction, the director now directly owns 35,000 shares of the company’s stock, valued at $199,150. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the acquisition, the director now owns 35,000 shares of the company’s stock, valued at approximately $199,150. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the sale, the insider now directly owns 4,716 shares of the company’s stock, valued at $27,258.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 15,000 shares of company stock worth $82,550. 2.76% of the stock is currently owned by company insiders.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.